BioMark Diagnostics Inc. (BMKDF)
USD 0.18
(0.0%)
USD 0.18
(0.0%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 | 1.69 Million CAD | -9.74% |
| 2023 | 1.88 Million CAD | -10.7% |
| 2022 | 2.1 Million CAD | 104.19% |
| 2021 | 1.03 Million CAD | -4.12% |
| 2020 | 1.07 Million CAD | -14.16% |
| 2019 | 1.25 Million CAD | 31.69% |
| 2018 | 952.17 Thousand CAD | -13.8% |
| 2017 | 1.1 Million CAD | 87.84% |
| 2016 | 588.04 Thousand CAD | 613.87% |
| 2015 | 82.37 Thousand CAD | 1520.58% |
| 2014 | 5083.00 CAD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q3 | 1.9 Million CAD | 7.0% |
| 2024 Q1 | 1.86 Million CAD | -0.97% |
| 2024 Q2 | 1.78 Million CAD | -4.27% |
| 2024 Q4 | 1.69 Million CAD | -11.03% |
| 2024 FY | 1.69 Million CAD | -9.74% |
| 2023 FY | 1.88 Million CAD | -10.7% |
| 2023 Q3 | 1.75 Million CAD | 0.32% |
| 2023 Q4 | 1.88 Million CAD | 7.24% |
| 2023 Q2 | 1.74 Million CAD | 1.68% |
| 2023 Q1 | 1.72 Million CAD | -18.37% |
| 2022 Q3 | 1.86 Million CAD | 99.99% |
| 2022 Q1 | 891.01 Thousand CAD | -13.66% |
| 2022 FY | 2.1 Million CAD | 104.19% |
| 2022 Q4 | 2.1 Million CAD | 13.18% |
| 2022 Q2 | 930.96 Thousand CAD | 4.48% |
| 2021 Q4 | 1.03 Million CAD | -1.93% |
| 2021 FY | 1.03 Million CAD | -4.12% |
| 2021 Q1 | 1.08 Million CAD | 0.92% |
| 2021 Q3 | 1.05 Million CAD | -0.41% |
| 2021 Q2 | 1.05 Million CAD | -2.73% |
| 2020 FY | 1.07 Million CAD | -14.16% |
| 2020 Q4 | 1.07 Million CAD | 0.74% |
| 2020 Q3 | 1.06 Million CAD | -1.45% |
| 2020 Q2 | 1.08 Million CAD | 1.72% |
| 2020 Q1 | 1.06 Million CAD | -14.99% |
| 2019 Q4 | 1.25 Million CAD | 6.65% |
| 2019 FY | 1.25 Million CAD | 31.69% |
| 2019 Q3 | 1.17 Million CAD | 11.54% |
| 2019 Q2 | 1.05 Million CAD | 5.62% |
| 2019 Q1 | 998.06 Thousand CAD | 4.82% |
| 2018 Q1 | 1.13 Million CAD | 2.59% |
| 2018 FY | 952.17 Thousand CAD | -13.8% |
| 2018 Q4 | 952.17 Thousand CAD | 0.62% |
| 2018 Q3 | 946.34 Thousand CAD | 1.84% |
| 2018 Q2 | 929.25 Thousand CAD | -18.0% |
| 2017 Q2 | 764.72 Thousand CAD | 22.75% |
| 2017 FY | 1.1 Million CAD | 87.84% |
| 2017 Q4 | 1.1 Million CAD | 29.78% |
| 2017 Q3 | 851.15 Thousand CAD | 11.3% |
| 2017 Q1 | 622.98 Thousand CAD | 5.94% |
| 2016 Q2 | 309.92 Thousand CAD | 84.6% |
| 2016 Q1 | 167.88 Thousand CAD | 103.81% |
| 2016 Q3 | 553.5 Thousand CAD | 78.6% |
| 2016 FY | 588.04 Thousand CAD | 613.87% |
| 2016 Q4 | 588.04 Thousand CAD | 6.24% |
| 2015 Q4 | 82.37 Thousand CAD | -46.48% |
| 2015 Q1 | - CAD | 0.0% |
| 2015 Q2 | 1000.00 CAD | 0.0% |
| 2015 Q3 | 153.9 Thousand CAD | 15290.8% |
| 2015 FY | 82.37 Thousand CAD | 1520.58% |
| 2014 FY | 5083.00 CAD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| American Bio Medica Corporation | 3.6 Million USD | 52.923% |
| Arrayit Corporation | 7.49 Million USD | 77.343% |
| Atlantic International Corp. | 3.82 Million USD | 55.636% |
| Biocept, Inc. | 22.01 Million USD | 92.284% |
| Bioqual, Inc. | 18.93 Million USD | 91.031% |
| CardioGenics Holdings Inc | 1.79 Million USD | 5.371% |
| DermTech, Inc. | 64.75 Million USD | 97.377% |
| Global WholeHealth Partners Corporation | - USD | -Infinity% |
| Hangzhou Tigermed Consulting Co., Ltd. | 734.97 Million USD | 99.769% |
| HTG Molecular Diagnostics, Inc. | 12.38 Million USD | 86.287% |
| iMD Companies, Inc. | 1.67 Million USD | -1.452% |
| IDenta Corp. | 1.01 Million USD | -67.647% |
| Interpace Biosciences, Inc. | 28.15 Million USD | 93.968% |
| Integrative Health Technologies, Inc. | 297.94 Thousand USD | -470.077% |
| InVitro International | 78.99 Thousand USD | -2050.305% |
| Lumos Diagnostics Holdings Limited | 19.72 Million USD | 91.391% |
| Many Bright Ideas Technologies Inc. | 129.29 Thousand USD | -1213.662% |
| Medical Imaging Corp. | 9.51 Million USD | 82.153% |
| NovelStem International Corp. | 4.2 Million USD | 59.617% |
| Optigenex Inc. | 9.57 Million USD | 82.253% |
| PharmChem, Inc. | 558.64 Thousand USD | -204.043% |
| Proteome Sciences plc | 18.48 Million USD | 90.813% |
| Response Genetics, Inc | 15.86 Million USD | 89.295% |
| Rennova Health, Inc. | 49.66 Million USD | 96.58% |
| RushNet, Inc. | 6.23 Million USD | 72.776% |
| ScreenPro Security Inc. | 1.6 Million USD | -6.119% |
| Stella Diagnostics Inc. | 18 Million USD | 90.567% |
| StageZero Life Sciences Ltd. | 8.2 Million USD | 79.296% |
| Todos Medical Ltd. | 50.15 Million USD | 96.614% |